MedTrace Logo

Dermal and Ophthalmological Acceptability Assessment in Sensitive Skin

NCT07771998 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2026-08-19

No results posted yet for this study

Summary

This is a single-center, single-blind clinical study designed to evaluate the safety of the investigational product through dermatological and ophthalmological clinical assessments. A total of 33 female participants, aged 18 to 60 years, with a clinical diagnosis of sensitive skin confirmed by the Stinging Test, will be enrolled. Safety evaluations will be performed throughout the study period using standardized clinical assessments.

Conditions

  • Sensitive Skin

Interventions

OTHER

Blancy Pro

Blancy Pro is a cosmetic product evaluated for safety and tolerability in female participants with clinically confirmed sensitive skin through dermatological and ophthalmological assessments.

Sponsors & Collaborators

  • Brainfarma Industria Química e Farmacêutica S/A

    lead INDUSTRY

Principal Investigators

  • Sergio Schalka · Grupo Medcin

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-20
Primary Completion
2026-09-03
Completion
2026-09-03

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07771998 on ClinicalTrials.gov